A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 2, 2016, Pages 181-188

  Curno, Mirjam J ^a,b   Rossi, Samuela ^a,c   Hodges Mameletzis, Ioannis ^a,d   Johnston, Rowena ^e   Price, Matt A ^f,g   Heidari, Shirin ^a,h  

^a UNAIDS   (Switzerland)

^b EPFL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Foundation for AIDS Research   (United States)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Inforia   (Switzerland)

Author keywords

antiretroviral drugs; clinical trials; curative strategies; eradication; gender; HIV; sex; vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ANTIRETROVIRUS AGENT;

ARTICLE; CLINICAL RESEARCH; FEMALE; FUNDING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; CLINICAL TRIAL (TOPIC); HIV INFECTIONS; MEDICAL RESEARCH; UNITED STATES;

AIDS VACCINES; ANTI-RETROVIRAL AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; UNITED STATES;

EID: 84955678258     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000842     Document Type: Article

References (43)

1. Cook MB, Dawsey SM, Freedman ND, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009; 18:1174-1182.
2. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173: 600-609.
3. McClelland EE, Smith JM. Gender specific differences in the immune response to infection. Arch Immunol Ther Exp (Warsz). 2011;59: 203-213.
4. Regitz-Zagrosek V. Sex and gender differences in health. Science & society series on sex and science. EMBO Rep. 2012;13:596-603.
5. Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.
6. FDA. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2013. Available at: www.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf. Accessed May 20, 2015.
7. Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol. 2006;2: 273-283.
8. Gesensway D. Reasons for sex-specific and gender-specific study of health topics. Ann Intern Med. 2011;135:935-938.
9. Krieger N. Genders, sexes, and health: what are the connections-and why does it matter? Int J Epidemiol. 2003;32:652-657.
10. Pinn VW. Sex and gender factors in medical studies: implications for health and clinical practice. JAMA. 2003;289:397-400.
11. Padian NS, Shiboski SC, Glass SO, et al. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol. 1997;146:350-357.
12. Gandhi M, Bacchetti P, Miotti P, et al. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35:313-322.
13. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol. 2008;168:532-540.
14. Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med. 2012;9:e1001304.
15. Druyts E, Dybul M, Kanters S, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS. 2013;27:417-425.
16. Maskew M, Brennan AT, Westreich D, et al. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt). 2013;22:113-120.
17. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003;11:55-59.
18. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination anti-retroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170: 57-65.
19. Berlin JA, Ellenberg SS. Inclusion of women in clinical trials. BMC Med. 2009;7:56.
20. Parekh A, Fadiran EO, Uhl K, et al. Adverse effects in women: implications for drug development and regulatory policies. Expert Rev Clin Pharmacol. 2011;4:453-466.
21. NIH. S.1-National Institutes of Health Revitalization Act of Subtitle B-Clinical Research Equity Regarding Women and Minorities Part I-Women and Minorities as Subjects in Clinical Research. Washington, DC; NIH: 1993.
22. FDA. Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation in Drugs. Washington, DC; FDA: 1993.
23. NIH. NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research-Amended, October, 2001. Washington, DC; NIH: 2001.
24. Geller SE, Koch A, Pellettieri B, et al. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress? J Womens Health (Larchmt). 2011;20:315-320.
25. Jagsi R, Motomura AR, Amarnath S, et al. Under-representation of women in high-impact published clinical cancer research. Cancer. 2009; 115:3293-3301.
26. Kim ESH, Menon V. Status of women in cardiovascular clinical trials. Arteriosclerosis Thromb Vasc Biol. 2009;29:279-283.
27. Poon R, Khanijow K, Umarjee S, et al. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009. J Womens Health (Larchmt). 2013;22:604-616.
28. Pinnow E, Sharma P, Parekh A, et al. Increasing participation of women in early phase clinical trials approved by the FDA. Womens Health Issues. 2009;19:89-93.
29. Weinberger AH, McKee S, Mazure CM. Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression. J Womens Health (Larchmt). 2010;19:1727-1732.
30. UNAIDS. Global Report. UNAIDS Report on the Global AIDS Epidemic 2013. Geneva, Switzerland; UNAIDS: 2013.
31. Soon GG, Min M, Struble K, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS. 2012;26:444-453.
32. Pardo MA, Ruiz MT, Gimeno A, et al. Gender bias in clinical trials of AIDS drugs. Abstract ID 6508. Paper presented at: The XIV International AIDS Conference; Barcelona, Spain, July 7-12, 2002.
33. Chilet-Rosell E, Ruiz-Cantero MT, Horga JF. Women's health and gender-based clinical trials on etoricobix: methodological gender bias. J Public Health. 2009;31:434-445.
34. Johnson SM, Karvonen CA, Phelps CL, et al. Assessment of analysis by gender in the cochrane reviews as related to treatment of cardiovascular disease. J Womens Health (Larchmt). 2003;12:449-457.
35. Kim ESH, Carrigan TP, Menon V. Enrollment of women in National Heart, Lung, and Blood Institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion. J Am Coll Cardiol. 2008;52:672-673.
36. Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010;3:135-142.
37. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291: 2720-2726.
38. CDC. HIV in the United States: At A Glance. Washington, DC; CDC: 2013:5.
39. Mills E, Nixon S, Singh S, et al. Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge. PLoS Med. 2006;3:e94.
40. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112:228-242.
41. Stein MD, Crystal S, Cunningham WE, et al. Delays in seeking HIV care due to ompeting caregiver responsibilities. Am J Public Health. 2002;90: 1138-1140.
42. Van Spall HGC, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals. A systematic sampling review. JAMA. 2007;297:1233-1240.
43. Falcon R, Bridge DA, Currier J, et al. Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt). 2011;20:1043-1050.